medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2004, Number S1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2004; 17 (S1)

New and experimental therapies for pulmonary hypertension

Sánchez MMA, Morales BJE

Language: Spanish
References: 34
Page: 52-61
PDF size: 89.87 Kb.


ABSTRACT

New medical treatments have been applied to the primary pulmonary arterial hypertension (PPH) patients. Those treatments began since 1990 with the epoprostenol introduction, which was a great deal in the study of this disease. Advances in the treatment have emerged because there is a best knowledge about different physiological mechanisms on pulmonary vascular endothelium, the latter plays an important role and we know more about the natural history of this entities associated to PHT.
A reduced spectrum of the conventional therapy with diuretics, anticoagulants, calcium-antagonism and oxygen, the last one have been better with a new drugs as prostacyclin, bosentan, iloprost, beraprost and treprostinil, but another new drugs as sildenafil, setaxsentan and ambrisentan are being studied. At the moment the development for new investigations looking for other therapeutic alternatives as gene therapy. An appropriated and individualized treatment for each patient, depend of multiples factors, as the experience in the equipment management in the drug administration to the patients and the preferences for the medical team, patients tolerance, the cost of each treatment and the availability of such drugs.


REFERENCES

  1. Rich S, Danzker DR, Ayres SM, Brundage BH, Detre KM, Fishman AP, et al. Primary Pulmonary Hypertension: a National Prospective Study. Ann Intern Med 1987;107:216-223.

  2. Runo JR, Loyd JE. Primary Pulmonary Hipertension. Lancet 2003;361:1533-1544.

  3. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. J Clin Pharmacol 2004; 44(1):83-88.

  4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hipertensión. Am J Respir Crit Care Med 2002;165:800-804.

  5. Pharmaceutical Approvals Monthly FDC reports. Chevy Chase, MD, USA, 2002;7(6):56.

  6. Hamilton G, Saba T, Corris P, Delcroix M, Simmoneau G, Sitbon O, et al. Improvement of Exercise Tolerance due to Uniprost in Patients with Pulmonary Arterial Hypertension is Related to Baseline Performance. Am J Respir Crit Care Med 2001;163:A540.

  7. Barst RJ, Horn EM, Widlitz AC. Efficacy of Long-term Subcutaneous Infusion of UT-15 in Primary Pulmonary Hypertension. Eur Heart J 2000;21:104-115.

  8. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of Pulmonary Arterial Hypertension: a Preliminary Decision Analysis. Chest 2003Dec;124(6):2087-92.

  9. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Ann Intern Med 1996;124:820-824.

  10. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Woll.brük B, Grimminger F, Seeger W. Recovery from Circulatory Shock in Severe Pulmonary Hypertension (PPH) with Aerosolization of Iloprost. Intensive Care Med 1998;24:631-634.

  11. Hoeper MM, Olschewski H, Ghofrani HA, Wikens H, Winkler J, Borst MM, et al. Comparison of the Acute Hemodynamic Effects of Inhaled Nitric Oxide and Aerosolized Iloprost in Primary Pulmonary Hypertension. German PPH Study Group. J Am Cardioll 2000;35:176-182.

  12. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. N Engl J Med 2002;347: 322-329.

  13. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long Term Treatment of Primary Pulmonary Hypertension with Aerolized Iloprost, a Prostacyclin Analogue. N Engl J Med 2000;342:1866-1870.

  14. Galie N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, et al. Effects of Beraprost Sodium, an Oral Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: a Randomized, Double-blind, Placebo-controlled Trial. J Am Coll Cardiol 2002;39: 1496-1502.

  15. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D, et al. Long Term Treatment of Pulmonary Arterial Hypertension with Beraprost, an Oral Prostacyclin Analogue. Heart 2001;86:661-665.

  16. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, et al. Effect of Orally Active Prostacyclin Analogue on Survival of Outpatients with Primary Pulmonary Hypertension. J Am Coll Cardiol 1999;34:1188-1192.

  17. Cacoub P, Dorent R, Nafat P, Carayon A, Riquet M, Noe E, et al. Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. Cardiovasc Res 1997;33:196-200.

  18. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the Dual Endothelin-receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: a Randomized Placebo-controlled Study. Lancet 2001;358:1119-1123.

  19. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. BREATH: Bosentan in Patients with Pulmonary Artery Hypertension: A Randomized, Placebo Controlled, Multicenter Study. N Engl J Med 2002;346:896-903.

  20. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Puliod T, et al. Effects of the Oral Endothelin-receptor Antagonist Bosentan on Echocardiographic and Doppler Measures in Patients with Pulmonary Arterial Hypertension. J Am Coll Cardiol 2003;41:1380-1386.

  21. Hoeper MH, Galie N, Simonneau G, Rubin LJ. New Treatments for Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2002;165:1209-1216.

  22. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical Efficacy of Sixtasentan, an Endotelin-a Receptor Antagonist, in Patients with Pulmonary Arterial Hypertension: Open-label Pilot Study. Chest 2002;121:1860.

  23. Archer S, Hampl V, McKenzie Z. Role of Endothelial-derived Nitric Oxide in Normal and Hypertensive Pulmonary Vasculature. Semin Respir Crit Care Med 1994;15:179-189.

  24. Giaid A, Saleh D. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. N Engl J Med 1995;333:214-221.

  25. Peinado VI, Barbera JA, Ramírez J, Gómez FP, Roca J, Jover L, et al. Endothelial Dysfunction in Pulmonary Arteries of Patients with Mild COPD. Am J Physiol 1998;274:L908-L913.

  26. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, et al. Impairment of Endothelium-Dependent Pulmonary-Artery Relexation in COPD. N Engl J Med 1991;324:1539-1547.

  27. Channick RN, Yung GL. Long-term Use of Inhaled Nitric Oxide for Pulmonary Hypertension. Respir Care 1999;109:1545-1549.

  28. Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, et al. Short-term Oral Administration of I-arginine Improves Hemodinamics and Exercise Capacity in Patients with Precapillary Pulmonary Hypertension. Am J Respir Crit Care Med 2001;163:887-891.

  29. Morris C, Morris S, Hagar W, Waderman J, Claster S, Kepka-Lenhart D, et al. Arginine Therapy. A New Treatment for Pulmonary Hypertension in Sickle Cell Disease? Am J Respir Crit Care Med 2003;168:63-69.

  30. Zhao L, Mason NA, Morrell NW, Kojonazarov A, Sadykov A, Maripov A, et al. Sildenafil Inhibits Hypoxia-induced Pulmonary Hypertension. Circulation 2001;104:424.

  31. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients with Primary Pulmonary Hypertension. Circulation 2001;104:1218-1222.

  32. Cowan KN, Heilnut A, Humpl T. Complete Reversal of Fatal Pulmonary Hypertension in Rats by Serin Elastasa Inhibitor. Nat Med 2000;6:698.

  33. Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, et al. The effects of Vasoactive Intestinal Peptide on Monocrotaline Induced Pulmonary Hypertensive Rabbits Following Cardiopulmonary Bypass: A Comparative Study with Isoproterenol and Nitroglicerina. Cardiovasc Surg 2002; 10:138.

  34. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive Intestinal Peptide as a New Drug for Treatment of Primary Pulmonary Hypertension. J Clin Invest 2003;111:1339.




2020     |     www.medigraphic.com